Senores Pharmaceuticals share news, announcements and annual reports
NSE: SENORESBSE: 544319Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,324.30.
29 Oct: open ₹1,324.30, high ₹1,339.50, low ₹1,208.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,615 Cr841st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.53
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.60
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.38
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 10,74,00132.0% delivered
Senores Pharmaceuticals has 175 announcements on record, routine notices left out; 12 in the 30 days to 30 Oct 2026, the latest on 29 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Senores Pharmaceuticals quarterly results
The board met on 29 Oct 2026 to consider financial results
Notice filed 22 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Senores Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Senores Pharmaceuticals financials, year by year
Annual reports2
- Annual report, year to Mar 20269 Sep 2026
- Annual report, year to Mar 20255 Sep 2025
Investor presentations9
- Investor Presentation29 Oct 2026
- Investor Presentation27 Jul 2026
- Investor Presentation14 May 2026
- Investor Presentation20 Jan 2026
- Investor Presentation15 Dec 2025
4 earlier presentations
- Investor Presentation6 Nov 2025
- Investor Presentation23 Jul 2025
- Investor Presentation16 May 2025
- Investor Presentation23 Jan 2025
Earnings calls17
- Link of Recording29 Oct 2026
- Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.3 Aug 2026
- Audio recording of Earnings Conference Call for the quarter ended June 30, 202627 Jul 2026
- Transcript of Earnings Conference Call held on Thursday, May 14, 2026 for Q4FY2619 May 2026
- Audio recordings of Earnings Conference Call for the quarter and financial year ended March 31, 2026.14 May 2026
12 earlier call documents
- Transcript of Earnings Conference Call held on Tuesday, January 20, 2026 for Q3FY2627 Jan 2026
- Audio recordings of Earnings Conference Call for the quarter and nine months ended December 31, 2025.20 Jan 2026
- Transcript of Business Update Call held on December 16, 202522 Dec 2025
- Audio Recording of Business Update Call16 Dec 2025
- Transcript of Earnings Conference Call held on Thursday, November 06, 2025 for Q2 & H1FY2613 Nov 2025
- Link of Audio recording of Earnings Conference Call for quarter and half year ended September 30, 20256 Nov 2025
- Transcript of Earnings Conference Call held on Thursday, July 24, 2025 for Q1FY26.30 Jul 2025
- Link of Recording24 Jul 2025
- Transcript of Earnings Conference Call held on Friday, May 16, 2025 for Q4FY2522 May 2025
- Link of Recording16 May 2025
- Transcript30 Jan 2025
- Link of Audio Recording of Earnings Conference Call for the quarter and nine months ended December 31,202423 Jan 2025
Senores Pharmaceuticals share news and announcements
Newest first. Page 1 of 4.
Oct 2026
29 Oct · Business
29 Oct · Business
29 Oct · Business
29 Oct · Management
29 Oct · Business
29 Oct · Business
29 Oct · Results
23 Oct · Analysts
22 Oct · Analysts
22 Oct · Board meeting
16 Oct · Meeting
Sep 2026
25 Sep · Meeting
21 Sep
11 Sep · General Updates
Aug 2026
27 Aug · Analysts
26 Aug · General Updates
26 Aug · General Updates
24 Aug · Giving guarantees/indemnity/ becoming a surety for third party
20 Aug · Analysts
Jul 2026
27 Jul · Business
27 Jul · Business
27 Jul · Business
27 Jul · Business
27 Jul · Results
27 Jul · Results
2 Jul · Meeting
1 Jul · Analysts
Jun 2026
29 Jun · Board meeting
10 Jun · Management
9 Jun · Analysts
4 Jun · Analysts
May 2026
22 May · Analysts
20 May · Analysts
14 May · Business
14 May · Business
14 May · Business
14 May · Results
14 May · Results
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 29 Oct 2026Resultsdown 7.94%−8.9 pts vs Nifty 500market median −0.7% · volume 4.6× usual · delivery −13.9 pts against usual · The announcement
- 27 Jul 2026Resultsup 1.77%+0.7 pts vs Nifty 500market median −0.7% · five sessions −5.9% (−8.3 pts vs Nifty 500) · volume 1.5× usual · delivery −3.3 pts against usual · The announcement
- 11 Jun 2026Board or managers changedup 4.32%+4.9 pts vs Nifty 500market median 0.0% · five sessions +14.1% (+10.2 pts vs Nifty 500) · volume 1.1× usual · delivery −11.0 pts against usual · The announcement
- 14 May 2026Resultsdown 1.96%−3.0 pts vs Nifty 500market median −0.7% · five sessions +11.3% (+10.4 pts vs Nifty 500) · volume 5.5× usual · delivery −23.3 pts against usual · The announcement
- 20 Jan 2026Resultsdown 2.66%−0.8 pts vs Nifty 500market median −0.7% · five sessions −1.8% (+0.5 pts vs Nifty 500) · volume 4.2× usual · delivery −27.6 pts against usual · The announcement
- 6 Nov 2025Resultsup 4.97%+5.7 pts vs Nifty 500market median −0.7% · five sessions +1.3% (+0.6 pts vs Nifty 500) · volume 10.6× usual · delivery −26.2 pts against usual · The announcement
- 25 Jul 2025Resultsdown 1.46%−0.2 pts vs Nifty 500market median −0.7% · five sessions +1.5% (+3.1 pts vs Nifty 500) · volume 2.2× usual · delivery −16.0 pts against usual · The announcement
Senores Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.